Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical efficacy and safety of lamotrigine monotherapy in newly diagnosed pediatric patients with epilepsy

간질 환아에서 Lamotrigine 초기 단독 요법의 효능 및 안정성에 대한 연구

  • Han, Ji-Hye (Department of Pediatrics, Chonbuk National University Medical School) ;
  • Oh, Jung-Eun (Department of Pediatrics, Chonbuk National University Medical School) ;
  • Kim, Sun-Jun (Department of Pediatrics, Chonbuk National University Medical School)
  • 한지혜 (전북대학교 의학전문대학원 소아과학교실) ;
  • 오정은 (전북대학교 의학전문대학원 소아과학교실) ;
  • 김선준 (전북대학교 의학전문대학원 소아과학교실)
  • Received : 2009.12.28
  • Accepted : 2010.03.02
  • Published : 2010.04.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : To verify the efficacy and safety of lamotrigine (LTG) monotherapy in newly diagnosed children with epilepsy. Methods : We prospectively enrolled 148 children who had undergone LTG monotherapy at our institution between September 2002 and June 2009. Twenty-nine patients were excluded: 19 due to incomplete data and 10 were lost to follow up. The data of the remaining 119 patients was analyzed. Results : We enrolled 119 pediatric epilepsy patients (aged 2.8-19.3 years; 66 males and 53 females) in this study. Out of 119 patients, 29 (25.2%) had generalized epilepsy and 90 (74.8%) had partial epilepsy. The responses of seizure reduction were as follows: Seizure freedom (no seizure attack for at least 6 months) in 87/111 (78.4%, n=111) patients; partial response (reduced seizure frequency compared to baseline) in 13 (11.7%) patients; and persistent seizure in 11 (9.9%) patients. The seizure freedom rate was in 81.6% in patients with partial seizure (75.9% for complex partial seizure and 90.9% for benign rolandic epilepsy) and 44.8% in patients with generalized epilepsy (30.0% for absence seizure, 35.7% for juvenile myoclonic epilepsy patients, and 100.0% for idiopathic generalized epilepsy patients). Adverse reactions were reported in 17 (14.3%) patients, and 8 patients (6.7%) discontinued LTG because of rash and tic. No patient experienced severe adverse reaction such as Stevens-Johnson syndrome. Conclusion : LTG showed excellent therapeutic response and had few significant adverse effects. Our findings report may contribute in promoting the use of LTG monotherapy in epileptic children.

목 적: LTG의 국외에서의 임상 연구는 다양한 발작과 간질증후군에 단일 또는 보조요법으로서 넓은 범위의 작용을 한다고 보고되었다. 국내에서는 아직까지 소아연령에서의 LTG 초기 단일요법에 대한 연구보고가 거의 없다. 이에 저자들은 단일 병원의 전향적 자료 분석을 통한 소아 간질 환자에서의 단일 LTG 약물요법의 효용성과 안정성에 대해 연구하고자 하였다. 방 법: 2002년 9월부터 2009년 6월까지 간질약 복용 병력이 없이 간질로진단 받고 LTG을 복약하였던 소아 환자 148명을 대상으로 전향적 연구를 통해 효용성과 안정성을 연구하였다. 결 과: 대상 환아 중 초기 단일 요법으로 LTG을 복용 후 최소 6개월간 외래 추적 관찰했을 때 발작이 전혀 없었던 환아(완전 관해군)는 87명(78.4%, n=111)이었고 발작 감소를 보인 환아(부분 관해군)는 13명(11.7%), 발작이 이전과 같은 빈도이거나 오히려 악화된 경우(발작 지속군)는 11명(9.9%)이었고 부작용인 피부발진과 틱 장애로 LTG복약을 중지해야만 했던 환아가 8명이었다. 발작의 유형에 따른 치료 결과는 완전 관해군을 기준으로 할 때 부분 간질에서 전신간질보다 발작 완해률이 81.6% vs 44.8 %로 더 높았다(${\kappa}^2$=26.75, $P$<0.05). 발작 유형별로는 각각 CPS가 41명(75.9%, n=54), BRE가 30명(90.9%, n=33) absence seizure가 3명(30.0%, n=10) JME가 5명(35.7%, n=14), IGE가 5명(100.0%, n=5)으로 완전 관해 되었고 IGE와 BRE에서 완전 관해률이 각각 100.0%, 90.9%로 높았다. 투약 기간 중 부작용이 관찰된 환아는 모두 17명(14.3%, n=119)이었다. 피부 발진이 11명, 틱 장애가 3명, 간염이 1명, 결막염이 1명, 졸림이 1명에서 관찰되었고 피부 발진이 생긴 환아 11명 중 7명은 발진이 심하여, 1명은 틱 증상이 심하여 투약을 중지하였다. Stevens-Johonson 증후군 같은 심각한 부작용이 생겼던 환아는 없었다. 결 론: 본 연구 결과 LTG 초기 단일요법의 효용성은 국외 보고와 비교하여 우수하거나 큰 차이가 없었으며, 위중한 부작용 사례는 없었다. 소아 간질 환자, 특히 양성 로란딕 간질 환자와 특발성 전신발작 환자에서 LTG의 초기 단일 요법 치료에 매우 우수한 것으로 사료되어 문헌 고찰과 함께 보고하는 바이다.

Keywords

References

  1. Von Wegerer J, Hesslinger B, Berger M, Walden J. A calcium antagonistic effect of the new antiepileptic drug lamotrigine. Eur Neuropsychopharmacol 1997;7:77-81. https://doi.org/10.1016/S0924-977X(96)00384-7
  2. Xie X, Lancaster B, Peakman T, Garthwaite J. Interaction of the antiepileptic drug lamotrigine with recombinant rat brain type IIA Na+channels and with native Na+channels in rat hippocampal neurons. Pflugers Arch 1995;430:437-46. https://doi.org/10.1007/BF00373920
  3. Goa KL, Ross SR, Chrisp P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993;46:152-76.
  4. Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatr Neurol 2000;23:160-3. https://doi.org/10.1016/S0887-8994(00)00162-4
  5. Duchowny M, Pellock JM, Graf WD, Billard C, Gilman J, Casale E et al. A placebo-controlled trials of lamotrigine add-on therapy for partial seizures in children. Neurology 1999;53:1724-31. https://doi.org/10.1212/WNL.53.8.1724
  6. Buchanan N. The efficacy of lamotrigine on seizure control in 34 children, adolescent and young adults with intellectual and physical disability. Seizure 1995;4:223-6.
  7. Coppola G, Auricchio G, Federico R, Carotenuto M, Pascotto A. Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures an openlabel, randomized, parallel-group study. Epilepsia 2004;45: 1049-53. https://doi.org/10.1111/j.0013-9580.2004.40903.x
  8. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox- Gastaut Study Group. N Engl J Med 1997;337:1807-12. https://doi.org/10.1056/NEJM199712183372504
  9. Frank LM, Enlow T, Holmes GL, Manasco P, Concannon S, Chen C et al. Lamictal(lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999;40:973-9. https://doi.org/10.1111/j.1528-1157.1999.tb00805.x
  10. Mikati MA, Holmes GL. Lamotrigine in absence and primary generalized epilepsies. J Child Neurol 1997;12 Suppl 1: S29-37. https://doi.org/10.1177/0883073897012001081
  11. Richens A, Yuen AW. Overview of the clinical efficacy of lamotrigine. Epilepsia 1991;32 Suppl 2:S13-6. https://doi.org/10.1111/j.1528-1157.1991.tb05880.x
  12. Commission on classification and terminology of the International League Against Epilepsy. Proposal for revised clinical and electrographic classification of epileptic seizures. In: Wyllie E. editor. The treatment of epilepsy. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2001:291-7.
  13. Timmings PL, Richens A. Lamotrigine as and add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol 1992;32:305-7. https://doi.org/10.1159/000116849
  14. Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 1992;13:107-12. https://doi.org/10.1016/0920-1211(92)90065-2
  15. Smith SE. al-Zubaidy ZA, Chapman AG, Meldrum BS. Excitatory amino acid antagonists, lamotrigine and BW 1003C87 as anticonvulsants in the genetically epilepsy-prone rat. Epilepsy Research 1993;15:101-11. https://doi.org/10.1016/0920-1211(93)90091-K
  16. Pellock JM. The clinical efficacy of lamotrigine as an antiepileptic drug. Neurology 1994;44 Suppl 8:S29-35
  17. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clinical Pharmacokinetics 1993;25:433-43. https://doi.org/10.2165/00003088-199325060-00003
  18. Gamble CL, Williamson PR, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database of Systematic Reviews, Issue 3, 2009.
  19. Prasad A, Kuzniecky RI, Knowlton RC, Welty TE, Martin RC, Mendez M, et al. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 2003;60:1100- 5. https://doi.org/10.1001/archneur.60.8.1100
  20. Pina-Garza JE, Elterman RD, Ayala R, Corral M, Mikati MA, Pina-Garza MJ et al. Long-term tolerability and efficacy of lamotrigine in infants 1 to 24 months old. J Child Neurol 2008;23:853-61. https://doi.org/10.1177/0883073808317348
  21. Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children Pediatr Neurol 2000;23:160-3. https://doi.org/10.1016/S0887-8994(00)00162-4
  22. Ignacio Valencia, Gerard Pinol-Ripoll, Divya S. Khurana, Huntley Hardison, Sanjeev V. Kothare, Joseph J.Melvin et al. Efficacy and safety of lamotrigine monotherapy in children and adolescents with epilepsy. Eur J Paediatr Neurol 2009; 13:141-5. https://doi.org/10.1016/j.ejpn.2008.03.002
  23. Coppola G, Licciardi F, Sciscio N, Russo F, Carotenuto M, Pascotto A. Lamotrigine as first-line drug in childhood absence epilepsy: a clinical and neurophysiological study. Brain Dev 2004;26:26-9. https://doi.org/10.1016/S0387-7604(03)00090-1
  24. Peltola J, Peltola M, Auvinen A, Raitanen J, Fallah M, Keranen T. Retention rates of new antiepileptic drugs in localization- related epilepsy: a single center study. Acta Neurol Scand 2009;119:55-60. https://doi.org/10.1111/j.1600-0404.2008.01062.x
  25. Duchowny M, Gilmaan J, Messenheimer J, Womble G, Risner M. Long-term tolerability and efficacy of lamotrigine in pediatric patients with epilepsy. J Child Neurol 2002;17: 278-85. https://doi.org/10.1177/088307380201700408
  26. Messenheimer JA, Giorgi L, Risner ME. The tolerability of lamotrigine in children. Drug Saf 2001;22:303-12.
  27. Shechter T, Shorter Z, Kramer U, Lerman-Sagie T, Ronen E, Rotem R et al. Adverse reaction of topiramate and lamotrigine in children. Pharmacoepidemiol Drug Saf 2005;14: 187-92. https://doi.org/10.1002/pds.1041